Adaptimmune Therapeutics PLC
NASDAQ:ADAP

Watchlist Manager
Adaptimmune Therapeutics PLC Logo
Adaptimmune Therapeutics PLC
NASDAQ:ADAP
Watchlist
Price: 0.253 USD 4.94% Market Closed
Market Cap: 67.1m USD
Section:
Wall Street Price Targets
Wall Street Price Targets
Revenue Forecast
Operating Income Forecast
Net Income Forecast
See Also
Price Target
Average
+535%
Revenue
Forecast
-11%
Operating Income
Forecast
-7%
Net Income
Forecast
-1%

Wall Street
Price Targets

ADAP Price Targets Summary
Adaptimmune Therapeutics PLC

Wall Street analysts forecast ADAP stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for ADAP is 1.608 USD with a low forecast of 0.465 USD and a high forecast of 3.15 USD.

ADAP Lowest Forecast
Wall Street Target
0.465 USD
84% Upside
ADAP Average Forecast
Wall Street Target
1.608 USD
535% Upside
ADAP Highest Forecast
Wall Street Target
3.15 USD
1 145% Upside
Lowest
Price Target
0.465 USD
84% Upside
Average
Price Target
1.608 USD
535% Upside
Highest
Price Target
3.15 USD
1 145% Upside
Adaptimmune Therapeutics PLC Competitors:
Price Targets
CVAC
CureVac NV
3% Downside
005690
Pharmicell Co Ltd
40% Upside
KMDA
Kamada Ltd
95% Upside
RAPT
Rapt Therapeutics Inc
281% Upside
CVAC
CureVac NV
3% Downside
005690
Pharmicell Co Ltd
40% Upside
KMDA
Kamada Ltd
95% Upside
RAPT
Rapt Therapeutics Inc
281% Upside
S
4599
StemRIM Inc
137% Upside
OPK
OPKO Health Inc
132% Upside
W
300142
Walvax Biotechnology Co Ltd
17% Downside
ARGX
argenx SE
48% Upside

Revenue
Forecast

Revenue Estimate
Adaptimmune Therapeutics PLC

For the last 8 years the compound annual growth rate for Adaptimmune Therapeutics PLC's revenue is 37%. The projected CAGR for the next 3 years is -11%.

37%
Past Growth
-11%
Estimated Growth
Estimates Accuracy
-6%
Average Miss
What are analyst estimates?

Operating Income
Forecast

Operating Income Estimate
Adaptimmune Therapeutics PLC

N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
-2%
Average Miss
What are analyst estimates?

Net Income
Forecast

Net Income Estimate
Adaptimmune Therapeutics PLC

N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
-47%
Average Miss
What are analyst estimates?

See Also

Summary
ADAP intrinsic value, competitors valuation, and company profile.
DCF Valuation
ADAP stock valuation using Discount Cash Flow valuation method.
Relative Valuation
ADAP stock valuation using valuation multiples.
Wall Street Estimates
ADAP price targets and financial estimates made by Wall st analysts.
Profitability Analysis
Detailed analysis of the company's profitability.
Solvency Analysis
Analysis of the financial position and solvency of the company.
Financials
Income Statement, Balance Sheet, Cash Flow Statement.
Discount Rate
ADAP stock discount rate: cost of equity and WACC.
Summary
DCF Valuation
Relative Valuation
Wall Street Estimates
Profitability Analysis
Solvency Analysis
Financials
Discount Rate
Discover More
Why do you have more estimates than other sites?

Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What is available on other sites you are seeing are mostly from the sell-side analysts.

What is ADAP's stock price target?
Price Target
1.608 USD

According to Wall Street analysts, the average 1-year price target for ADAP is 1.608 USD with a low forecast of 0.465 USD and a high forecast of 3.15 USD.

What is Adaptimmune Therapeutics PLC's Revenue forecast?
Projected CAGR
-11%

For the last 8 years the compound annual growth rate for Adaptimmune Therapeutics PLC's revenue is 37%. The projected CAGR for the next 3 years is -11%.

Back to Top
ALPHA SPREAD
Follow us
Join more than 266,400+ value investors using Alpha Spread
Create Free Account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks Wide Economic Moat Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2025 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.